Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Anne Couvelard Benveniste

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6316-1210; OpenAlex author ID A5038626624. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
61
Papers, trials and grants by year

2012: 3 papers · 2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: none · 2018: 2 papers · 2019: 3 papers · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 2 papers

Papers 20

  1. Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach. Co-author DOI 10.1002/path.6398↗
  2. Comparison of radiological and pathological tools to assess response to neoadjuvant treatment in resected pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1177/17588359251403909↗
  3. Acinar-to-Ductal Metaplasia (ADM): On the Road to Pancreatic Intraepithelial Neoplasia (PanIN) and Pancreatic Cancer. Co-author DOI 10.3390/ijms24129946↗
  4. The Orexin-A/OX1R System Induces Cell Death in Pancreatic Cancer Cells Resistant to Gemcitabine and Nab-Paclitaxel Treatment. Co-author DOI 10.3389/fonc.2022.904327↗
  5. Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features. Co-author DOI 10.3390/cancers13061234↗
  6. Nucleolin Targeting by N6L Inhibits Wnt/β-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13122986↗
  7. Preclinical Evaluation of 68Ga-DOTA-NT-20.3: A Promising PET Imaging Probe To Discriminate Human Pancreatic Ductal Adenocarcinoma from Pancreatitis. Co-author DOI 10.1021/acs.molpharmaceut.9b00283↗
  8. Prognostic Biomarkers in Pancreatic Cancer: Avoiding Errata When Using the TCGA Dataset. Co-author DOI 10.3390/cancers11010126↗
  9. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. Co-author DOI 10.3390/cancers11111808↗
  10. Tumor Heterogeneity in Pancreatic Adenocarcinoma. Co-author DOI 10.1159/000477773↗
  11. In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.24084↗
  12. Dual Roles for CXCL4 Chemokines and CXCR3 in Angiogenesis and Invasion of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-15-2864↗
  13. Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature. Co-author DOI 10.1158/0008-5472.can-16-0300↗
  14. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Co-author DOI 10.1016/j.pharmthera.2015.08.006↗
  15. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. First author DOI 10.1111/his.12691↗
  16. EGFR expression in pancreatic adenocarcinoma. Relationship to tumour morphology and cell adhesion proteins. Last author DOI 10.1136/jclinpath-2013-201662↗
  17. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Co-author DOI 10.1007/s10555-012-9396-2↗
  18. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Co-author DOI 10.1053/j.gastro.2012.06.006↗
  19. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Co-author DOI 10.1093/annonc/mdr617↗
  20. Biological and prognostic relevance of mitogen-activated protein kinases in pancreatic adenocarcinoma. Last author DOI 10.1097/mpa.0b013e318238379d↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jerome F. Cros · 10 shared papers, 2015–2025 · strength 1.11
  2. Vinciane Rebours · 6 shared papers, 2012–2025 · strength 0.80
  3. Jérôme Raffenne · 5 shared papers, 2018–2025 · strength 0.61
  4. Louis de Mestier · 4 shared papers, 2015–2025 · strength 0.56
  5. Alain Sauvanet Sauvanet · 8 shared papers, 2012–2025 · strength 0.51
  6. Rémy Nicolle · 4 shared papers, 2019–2025 · strength 0.50
  7. Valérie Paradis · 5 shared papers, 2015–2021 · strength 0.40
  8. Pascal R. Hammel · 8 shared papers, 2012–2021 · strength 0.37
  9. Cindy Neuzillet · 4 shared papers, 2013–2025 · strength 0.35
  10. Jean‐Baptiste Bachet · 5 shared papers, 2012–2021 · strength 0.27
  11. Thierry Voisin · 2 shared papers, 2018–2022 · strength 0.24
  12. Alain Couvineau · 2 shared papers, 2018–2022 · strength 0.24
  13. Magali Svrcek · 4 shared papers, 2012–2021 · strength 0.22
  14. Maxime Ronot · 1 shared paper, 2025 · strength 0.22
  15. Safi Dokmak · 1 shared paper, 2025 · strength 0.22
  16. Anaïs Jenvrin · 1 shared paper, 2025 · strength 0.22
  17. Anne‐Laure Védié · 1 shared paper, 2025 · strength 0.22
  18. Diane Lorenzo · 1 shared paper, 2023 · strength 0.22
  19. Cécile Haumaître · 1 shared paper, 2023 · strength 0.22
  20. Louis MARSTRAND-DAUCE · 1 shared paper, 2023 · strength 0.22
  21. Magali Richard · 1 shared paper, 2025 · strength 0.21
  22. Marc Hilmi · 1 shared paper, 2025 · strength 0.21
  23. Juan Iovanna · 1 shared paper, 2025 · strength 0.21
  24. Nelson Dusetti · 1 shared paper, 2025 · strength 0.21
  25. Philippe B Ruszniewski · 4 shared papers, 2012–2018 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.